基于纵向队列中多种抗体测量预测的中和滴度估算对COVID-19的保护力,法国,2020年4月至2021年11月
研究采集304份疫苗诱导或感染获得SARS-CoV-2免疫者的血清,建立抗体与中和滴度的预测模型,并据此推断对症状性和重症COVID-19的保护力。在905人法国纵向队列中估算群体免疫,结果显示三剂疫苗接种者对Delta变异株感染的症状性COVID-19风险降低中位数为96%(IQR:94-98),而感染获得免疫者仅为42%(IQR:22-66)。
要点
- 低成本高通量抗体检测与活病毒中和能力呈强相关。
- 三剂疫苗接种者对Delta感染风险降低中位数96%(IQR:94-98)。
- 感染获得免疫者风险降低中位数仅42%(IQR:22-66)。
核心结论
- 结果与疫苗有效性研究数据一致,表明该方法的稳健性。
- 多重血清学检测可便捷地适配研究新变异株,并为开发包含保护力估算的检测提供框架。
研究设计与样本
- 为关联抗体与中和滴度,采集304份具有疫苗诱导或感染获得SARS-CoV-2免疫的个体血清样本。
- 利用抗体与中和滴度的关联,建立SARS-CoV-2特异性中和滴度的预测模型。
- 基于预测中和滴度,利用既往描述的中和滴度与保护力估算关系推断对症状性和重症COVID-19的保护力。
- 在905人法国纵向队列中估算群体免疫,随访时间为2020年4月至2021年11月。
主要发现
- 使用低成本高通量检测测量的抗SARS-CoV-2抗体与活病毒中和抗体应答能力呈强相关。
- 单次疫苗接种或感染获得免疫的参与者尤其易感症状性或重症COVID-19。
- 三剂疫苗接种者中,Delta变异株感染所致COVID-19风险降低中位数为96%(IQR:94-98)。
- 感染获得免疫者中,风险降低中位数仅为42%(IQR:22-66)。
关键数值与推荐
- 三剂疫苗接种者Delta变异株感染所致COVID-19风险降低中位数96%(IQR:94-98)。
- 感染获得免疫者Delta变异株感染所致COVID-19风险降低中位数42%(IQR:22-66)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundThe risk of SARS-CoV-2 (re-)infection remains present given waning of vaccine-induced and infection-acquired immunity, and ongoing circulation of new variants.AimTo develop a method that predicts virus neutralisation and disease protection based on variant-specific antibody measurements to SARS-CoV-2 antigens.MethodsTo correlate antibody and neutralisation titres, we collected 304 serum samples from individuals with either vaccine-induced or infection-acquired SARS-CoV-2 immunity. Using the association between antibody and neutralisation titres, we developed a prediction model for SARS-CoV-2-specific neutralisation titres. From predicted neutralising titres, we inferred protection estimates to symptomatic and severe COVID-19 using previously described relationships between neutralisation titres and protection estimates. We estimated population immunity in a French longitudinal cohort of 905 individuals followed from April 2020 to November 2021.ResultsWe demonstrated a strong correlation between anti-SARS-CoV-2 antibodies measured using a low cost high-throughput assay and antibody response capacity to neutralise live virus. Participants with a single vaccination or immunity caused by infection were especially vulnerable to symptomatic or severe COVID-19. While the median reduced risk of COVID-19 from Delta variant infection in participants with three vaccinations was 96% (IQR: 94-98), median reduced risk among participants with infection-acquired immunity was only 42% (IQR: 22-66).ConclusionOur results are consistent with data from vaccine effectiveness studies, indicating the robustness of our approach. Our multiplex serological assay can be readily adapted to study new variants and provides a framework for development of an assay that would include protection estimates.
引用
- Woudenberg T, Pinaud L, Garcia L, et al. Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021. Euro Surveill. 2023. PMID: 37347417. doi:10.2807/1560-7917.ES.2023.28.25.2200681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。